06669.HK
Acotec Scientific Holdings Limited
HKSE · Healthcare · Medical - Devices · CN
HKD 5.90
−4.07%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 625.0M | 644.6M | 534.0M | 473.8M | 395.5M |
| Cost of Revenue | 176.0M | 168.3M | 131.3M | 96.4M | 59.2M |
| Gross Profit | 449.0M | 476.3M | 402.7M | 377.4M | 336.4M |
| Operating Expenses | |||||
| R&D Expense | 350.7M | 213.7M | 216.8M | 190.1M | 183.8M |
| SG&A Expense | 162.1M | 182.3M | 157.6M | 181.3M | 160.5M |
| General & Admin Expense | 71.6M | 76.9M | 64.9M | 83.8M | 87.8M |
| Selling & Marketing Expense | 90.5M | 105.5M | 92.8M | 97.5M | 72.7M |
| Other Expenses | (26.5M) | (52.8M) | (35.6M) | (19.0M) | (80.0M) |
| Total Operating Expenses | 486.2M | 343.2M | 338.7M | 352.4M | 264.3M |
| Cost and Expenses | 662.2M | 511.5M | 470.0M | 448.8M | 323.5M |
| Operating Income (EBIT) | (37.2M) | 133.2M | 64.0M | 25.0M | 72.1M |
| Non-Operating | |||||
| Interest Income | — | 25.7M | 30.1M | 18.5M | 20.3M |
| Interest Expense | — | 9.4M | 11.5M | 9.8M | 1.4M |
| Net Interest Income | 13.0M | 16.3M | 18.6M | 8.7M | 18.8M |
| Other Non-Op Income/Expense | (10.7M) | (11.0M) | (11.4M) | (10.6M) | (1.8M) |
| Non-Operating Income (excl Interest) | 12.4M | 27.3M | 1.5M | 724.0K | 341.0K |
| EBT (Pre-Tax Income) | (47.9M) | 122.2M | 52.6M | 14.5M | 70.3M |
| Income Tax Expense | 2.4M | 3.0M | 321.0K | (35.0K) | 177.0K |
| Bottom Line | |||||
| Net Income | (50.2M) | 119.2M | 52.3M | 14.5M | 70.1M |
| Earnings from Cont. Ops | (50.2M) | 119.2M | 52.3M | 14.5M | 70.1M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (50.2M) | 119.2M | 52.3M | 14.5M | 70.1M |
| Per Share | |||||
| Basic EPS | (HK$0.16) | HK$0.39 | HK$0.17 | HK$0.05 | HK$0.23 |
| Diluted EPS | (HK$0.16) | HK$0.39 | HK$0.17 | HK$0.05 | HK$0.23 |
| Revenue Per Share | HK$2.09 | HK$2.13 | HK$1.77 | HK$1.57 | HK$1.32 |
| Shares | |||||
| Basic Shares Outstanding | 299.4M | 301.9M | 301.1M | 301.1M | 299.6M |
| Diluted Shares Outstanding | 302.1M | 301.9M | 301.1M | 301.1M | 299.6M |
| Profitability Metrics | |||||
| EBITDA | (26.5M) | 129.6M | 112.5M | 70.5M | 91.2M |
| D&A | 23.2M | 23.8M | 50.0M | 46.3M | 19.4M |
| EBIT | (49.7M) | 105.8M | 62.5M | 24.3M | 71.7M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026